Figure 4. In vivo antitumor efficacy of Norvaline/Sunitinib and CuS/NorSun NCs against A549 tumor xenografts. (A) Representative images of excised tumors from mice after treatment with Norvaline/Sunitinib (4 mg/kg) and CuS/MDSCs NCs (5 mg/kg) (B) Relative tumor volumes of A549 tumor bearing mice following treatment. Relative tumor volumes (V/V₀) of A549 tumor bearing mice following intravenous administration of Norvaline/Sunitinib and CuS/MDSCs NCs. Data represent the mean ±SD of three independent experiments (*P < 0.05; **P < 0.01).